Physician profile
Hazel Yang
NPI 1831196807
$6,799.09
in general payments reported to CMS, 2019-2025
25 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,488 · 2020: $1,216 · 2021: $709 · 2022: $738 · 2023: $689 · 2024: $914 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,648.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,215.42 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,088.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $694.14 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $605.44 | 2019-2023 | Steglujan, Steglatro |
| Astrazeneca Pharmaceuticals Lp | $551.76 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $403.52 | 2019-2022 | |
| Dexcom, INC. | $384.27 | 2019-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $330.06 | 2020-2025 | Omnipod |
| Amgen INC. | $222.32 | 2019-2020 | |
| Medtronic, INC. | $219.08 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Abbott Laboratories | $183.19 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $155.91 | 2023-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $144.50 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $135.92 | 2019-2022 | |
| Radius Health, INC. | $100.10 | 2024-2025 | Tymlos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $86.19 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $75.66 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $50.76 | 2024-2025 | Unithroid |
| Medtronic Minimed, INC. | $46.54 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.11 | 2022 | |
| Ascendis Pharma Endocrinology INC | $19.77 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $17.74 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $15.56 | 2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $12.36 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.